2021 年第 5 期 第 16 卷

米那普仑治疗纤维肌痛症的研究进展

Research progress of milnacipran in treatment of fibromyalgia

作者：杜秋燕蒋常莲刘莉叶兰仙

英文作者：Du Qiuyan Jiang Changlian Liu Li Ye Lanxian

单位：兰州大学第二医院心理卫生科730030

英文单位：Department of Mental Health Lanzhou University Second Hospital Lanzhou 730030 China

关键词：纤维肌痛症；米那普仑；研究进展

英文关键词：Fibromyalgia；Milnacipran；Researchprogress

• 摘要：

• 纤维肌痛症也称纤维肌痛综合征，因其广泛的症状学特征和极高的共病率已成为一种高度致残疾病，临床误诊率高，患者极易伴发抑郁情绪而导致病情加重，目前其发病机制尚不明确。米那普仑是一种特异性5-羟色胺和去甲肾上腺素再摄取抑制剂，能同等强度地抑制神经末梢对5-羟色胺和去甲肾上腺素的再摄取，临床上主要用于抑郁症及纤维肌痛症的治疗。本文对米那普仑治疗纤维肌痛症的可能机制、临床效果及安全性等进行综述，以期为米那普仑在纤维肌痛症中的应用提供参考。

• Fibromyalgia, also known as fibromyalgia syndrome, has become a highly disabling disease due to its extensive symptomatic characteristics and high rate of comorbidities. The misdiagnosis rate is high, and it is easy to be accompanied by depression, which leads to exacerbation of the condition. At present, the pathogenesis is not clear. Milnacipran is a specific serotonin and norepinephrine reuptake inhibitor, which can inhibit the reuptake of serotonin and norepinephrine by nerve endings with equal intensity. It is mainly used in the clinical treatment of depression and fibromyalgia. This article reviews the possible mechanism, clinical efficacy and safety of milnacipran in the treatment of fibromyalgia, in order to provide reference for the more scientific application of milnacipran in fibromyalgia.